News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • NAND-driven gains highlight rising AI storage demand, benefiting storage suppliers.
  • Western Digital shows strong free cash flow and shrinking net debt while gaining cloud and AI customer revenue.
  • Trade idea: go long WDC to capture pricing leverage, using a tight stop for valuation risk.
  • Wolfspeed offers asymmetric upside from silicon carbide adoption across EVs, fast charging, and data centers.
  • Recommended Wolfspeed trade: disciplined long with a defined entry, protective stop, and a $40 target.
  • Semiconductor materials and AI storage themes could prompt near-term rotation into tech hardware stocks.

Latest Articles

Buy Globant (GLOB): A Practical Play on Software Resilience

Buy Globant (GLOB): A Practical Play on Software Resilience

Globant is a profitable, cash-generative IT services company trading at a subdued valuation after a steeper-than-expected pullback. With a market cap near $1.39B, a trailing P/E around 13, and improving technicals, this is a mid-term swing trade that bets on fundamentals holding and the market re-embracing software growth. Entry $32.23, stop $28.00…

Trump Media Settles Legal Disputes

Trump Media Settles Legal Disputes

Trump Media and Technology Group Corp. announced the resolution of legal disputes among multiple parties via a confidential settlement agreement. The company operates platforms including Truth Social, Truth+, and Truth.Fi, aiming to promote free speech and provide alternative social media, streaming, and fintech services. The settlement removes ong…

GEnx-1B Engines Surpass 50 Million Flight Hours

GEnx-1B Engines Surpass 50 Million Flight Hours

GE Aerospace's GEnx-1B engine, powering the Boeing 787 Dreamliner, has surpassed 50 million flight hours in just over 14 years, marking the fastest achievement for GE's commercial widebody engines. The engine demonstrates exceptional reliability and durability with a 99.98% dispatch reliability rate. GE Aerospace is investing significantly in manuf…

Ambarella: Buy the New Edge-AI Product Cycle on a Measured Pullback

Ambarella: Buy the New Edge-AI Product Cycle on a Measured Pullback

Ambarella's new product cycle and rising share of AI-focused chips have transformed growth expectations. Revenue momentum, an improving automotive mix and a recent analyst upgrade make a compelling mid-term long trade from current levels. Valuation is rich on a P/S basis but justified if Ambarella sustains high-teens to mid-30s revenue growth and m…

DPM Metals: Buy the Re-rate - NAV Engine Still Mispriced

DPM Metals: Buy the Re-rate - NAV Engine Still Mispriced

DPM Metals is trading at $33.30 with a $7.37B market cap, a modest 13.2x PE and 2.7x PB. The market is failing to fully value the company’s NAV-creation pathway — converting resources into reserves and steady cash generation. This is a long-term trade: enter at $33.30, stop $29.00, target $46.28 over a 180-trading-day horizon. Risk is real (commodi…

STOK: A Mid-Window Trade as STK-001 Nears Its Final Readout Stretch

STOK: A Mid-Window Trade as STK-001 Nears Its Final Readout Stretch

Stoke Therapeutics is approaching a critical phase for its lead program STK-001 in Dravet syndrome. The company has a solid liquidity cushion relative to enterprise value, a history of data-driven jumps, and elevated short interest that can accelerate moves. This trade targets a mid-term rebound into potential milestone-driven re-rating while keepi…

Mattel: Deep Value Play with Clear Catalysts and a Path to $20

Mattel: Deep Value Play with Clear Catalysts and a Path to $20

Mattel is trading at a single-digit earnings multiple, generating positive free cash flow, and sitting on strong global franchises. Near-term noise on margins and FX has driven the stock lower; we see a disciplined long trade with defined risk and 40-80% upside if catalysts play out over the next 3-6 months.

Macy's: Turnaround Momentum, Cheap Valuation and a Clear Risk/Reward

Macy's: Turnaround Momentum, Cheap Valuation and a Clear Risk/Reward

Macy's has delivered its strongest quarter in years, raised guidance, and attracted a material stake from Berkshire Hathaway. At roughly $23.70 and trading below a single-digit P/E on some metrics, the stock offers a favorable risk/reward for a long trade. This idea lays out an entry at $24.00, a $30.00 target and a $20.50 stop, with a 180-trading-…

Teradyne 2027 Play: Buy the 2026 Dip With 2027 in Mind

Teradyne 2027 Play: Buy the 2026 Dip With 2027 in Mind

Teradyne has re-rated on AI-driven semiconductor test demand and robotics growth. Near-term lumpiness and margin noise will keep the stock volatile, but the company's scale in semicon test, improving cash generation, and index inclusion create a path to meaningful upside by 2027. This trade targets a recovery toward prior highs with a clear stop to…

Quanta Services: Buy the Grid Play Powering the AI Buildout

Quanta Services: Buy the Grid Play Powering the AI Buildout

Quanta Services sits at the physical intersection of AI demand and electric infrastructure. Backlog, free cash flow and a new buyback create a constructive setup despite a premium multiple. This is a swing trade: buy the pullback around current levels with a mid-term horizon while watching execution and margin trends closely.

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

4D Molecular Therapeutics revealed positive two-year results from its PRISM Phase 2b clinical trial for 4D-150, an intravitreal gene therapy targeting wet age-related macular degeneration (AMD). The therapy demonstrated sustained visual acuity, anatomical control, and a significant reduction in treatment burden with a favorable safety profile. Thes…